[ad_1]
News India Live, Digital Desk: US President Donald Trump has made a major announcement on pharma imports, which has created panic in the Indian pharmaceutical industry. Announcing a new trade policy on Thursday, he said that the US will impose tariffs (import duty) up to 100 percent on the import of branded and patented pharma products from 1 October 2025. This simply means that if foreign pharmaceutical companies do not set up their manufacturing plants in the US, they will have to pay a huge fee on their products.
This move of Trump administration is clearly designed to bring drug production back to US earth. Its biggest impact will be on major foreign exporters, including Indian drug manufacturers. India is a major drug exporter in the world and this new policy can become a major challenge for companies that export its branded and patented pharma products to the US.
It will be interesting to see how this policy applies and what strategy Indian pharmaceutical companies adopt to deal with it. Experts believe that this can change the nature of India’s drug export market to a great extent and forces companies to invest in the US or to seek alternative markets.
North India Statesman